Glenn Tillotson, PhD, FIDSA, discusses the costs of drug development.
Glenn Tillotson, PhD, FIDSA, consultant microbiologist in Durham, NC, discusses the costs of drug development.
Interview Transcript (modified slightly for readability):
“The costs of drug development obviously have escalated in the last 10-20 years. There is a group at Tufts University in Boston that undertake a fairly regular evaluation of the drug development process and the different components, including what the costs and timelines are for those different stages. I think it was in 2015 that a Tufts group published a report that said nowadays a drug—and I’m speaking holistically—will cost about $2.5 billion to an organization to develop and get approved and taken to the clinic. $2.5 billion.”